A study of IMR-687 for the treatment of sickle cell disease in adult patients

Trial Profile

A study of IMR-687 for the treatment of sickle cell disease in adult patients

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs IMR 687 (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Sponsors Imara Inc
  • Most Recent Events

    • 14 Sep 2017 According to an Imara media release, the company plans to initiate this study by end of 2017.
    • 23 May 2017 New trial record
    • 15 May 2017 According to an Imara media release, the company plans to initiate this study later in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top